GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com
Summary of Product Characteristics last updated on the eMC: 17/09/2009
SPC Rotarix

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/09/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   21-Aug-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

section 4.2 - Reference to use in preterm infants

section 4.3 -Removal of previous wording on use in HIV infants

section 4.4 - Wording on use in HIV infants. Removal of previous wording on use in premature children.

section 4.8 -Safety data in preterm infants and infants with HIV

section 5.1 - Immune response in preterm infants

section 6.3 -Revised in-use storage information

section 6.4 - Revised storage information

section 10 - Date of approval updated
Updated on 25/09/2008 and displayed until 17/09/2009
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Change to section 1 -Name of the Medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6.1 - List of Excipients
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 6. 3 - Shelf Life
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Sep-2008
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company



Section 1 - Administrative changes

Section 2 - Amendment to excipient statement and administrative changes

Section 4.2 - Administrative changes

Section 4.4 - Amendment to excipient statement and administrative changes

Section 4.6 - Administrative changes

Section 4.8 - Reordering of adverse events and administrative changes

Section 5.1 - Revised pharmaco-therapeutic group

Section 6.1 - Administrative changes

Setion 6.3 - Administrative changes

Section 6.5 - Administrative change

Section 6.6 - Administrative change

Section 10 - date of Commission Decision

 

 

Updated on 21/08/2008 and displayed until 25/09/2008
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 date of revision of the text
  • Change to section 5.1 - Pharmacodynamic Properties
Date of revision of text on the SPC:   19-Jun-2008
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Section 4.5 - update to wording regarding concomitant administration of OPV

Section 5.1 - update to include data from 2nd year of study 036

Section 10 - Approval date - 04/07/08
Updated on 05/02/2008 and displayed until 21/08/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   12/2007
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Section 4.4:  To include a warning on Apnoea
Section 4.8:  To include Apnoea as an Undesirable Effect
Section 10: Approval date of variation
Updated on 22/12/2006 and displayed until 05/02/2008
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 6. 6 - Instructions for use, handling and disposal
Date of revision of text on the SPC:   12/2006
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Several sections have changed.
Updated on 22/05/2006 and displayed until 22/12/2006
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   live attenuated rotavirus vaccine


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk